检索结果-南通市图书馆

Impact of erythropoietin therapy on cardiorenal syndrome:A systematic review with meta-analysis

World Journal of Cardiology 2023年第5期15卷 273-283页

作者： rubal bhangal Ivan Cancarevic Mahmoud Nassar Zaryab Umar Department of Internal Medicine Icahn School of Medicine at Mount Sinai/NYC Health+Hospitals QueensNew YorkNY 11432United States Department of Internal Medicine Icahn School of Medicine at Mount SinaiNew YorkNY 10029United States Department of Internal Medicine NYC Health+Hospital QueensNew YorkNY 11432United States

BACKGROUND Heart and kidney dysfunction frequently coexist in patients with acute heart failure due to the overlap between these two organ *** syndrome(CRS)results from pathology occurring in the heart and kidneys along with the consequences of dysfunction in one organ contributing to dysfunction in the other and vice *** To evaluate the use of erythropoietin(EPO)in patients with CRS and its effects on hemoglobin(Hb),major cardiovascular(CV)events,and hospitalization *** On February 24,2022,searches were conducted using PubMed,MEDLINE,and EMBASE,and 148 articles were identified.A total of nine studies were considered in this systematic *** assessed the included articles based on the National Heart,Lung,and Blood Institute quality assessment tools for controlled intervention and observational cohort or cross-sectional *** assessment of bias risk was conducted on the chosen studies,and data relevant to our review was *** The systematic review of these studies concluded that most existing literature indicates that EPO improves baseline Hb levels and decreases myocardial remodeling and left ventricular dysfunction without reducing CV *** addition,the effect of EPO on the hospitalization rate of patients with CRS needs to be further studied since this relationship is *** studies,such as randomized controlled clinical trials and prospective cohort studies,should be conducted to enhance the literature on the potential of EPO therapy in patients with *** Our systematic review suggests that EPO therapy may have a significant role in managing *** review highlights the potential benefits of EPO in improving baseline Hb levels,reducing the risk of major CV events,improving cardiac remodeling,myocardial function,New York Heart Association class,and B-type natriuretic peptide ***,the effect of EPO treatment on hospitalization remains unclear and needs further exploration.

关键词： Cardiorenal syndrome Anemia Cardiovascular disease End-stage renal disease Erythropoietin Congestive heart failure

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：